Genglycos (pariglasgene brecaparvovec-opnr)
Intravenous Vial (Ml)
Last reviewed · Source: First Databank (FDB) drug data
Overview
Generic name: pariglasgene brecaparvovec-opnr
Therapeutic class: Biologicals
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Genglycos
Indications
The following indications are listed for Genglycos:
- Glycogen Storage Disease Type Ia
Also known as: Glucose-6-Phosphatase Deficiency, Glycogen Storage Disease Ia, Von Gierke Disease Type Ia.
Dosing
No dosing information is available for this tab.
No dosing information is available for this tab.
No dosing information is available for this tab.
No dosing information is available for this tab.
Drug interactions
There is no enhanced messaging for this drug.
Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient.
Pariglasgene Brecaparvovec/Vaccines
SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient.
MECHANISM OF ACTION: Pariglasgene brecaparvovec therapy may decrease the effectiveness of vaccines. The mechanism is not known.(1)
CLINICAL EFFECTS: The expected serum antibody response may not be obtained.(1)
PREDISPOSING FACTORS: None determined.
PATIENT MANAGEMENT: The US manufacturer of pariglasgene brecaparvovec states that vaccines should be avoided for 1 month prior to pariglasgene brecaparvovec administration.(1)
DISCUSSION: Pariglasgene brecaparvovec therapy may decrease the effectiveness of vaccines.(1)
There are no severe interactions for this drug.
There are no moderate interactions for this drug.
Contraindications
There is no enhanced messaging for this drug.
- Hepatic cirrhosis
- Hepatic fibrosis
There are no moderate contraindications for this drug.
Adverse reactions
There is no enhanced messaging for this drug.
More Frequent
- Abnormal hepatic function tests
- Drug-induced hepatitis
- Increased alanine transaminase
- Increased aspartate transaminase
Less Frequent
- Adrenocortical insufficiency
- Anaphylaxis
- Elevated blood lactate level
Rare or Very Rare
- Hypersensitivity drug reaction
- Hypoglycemic disorder
- Injection site sequelae
More Frequent
- Acne vulgaris
- Acneiform eruption
- Constipation
- Headache disorder
- Hyperglycemia
- Hypertriglyceridemia
- Nausea
Precautions
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
ICD codes
| Code | Type | Description |
|---|---|---|
| Glycogen storage disease type ia | ||
| E74.01 | ICD10CM | Von gierke disease |
ICD code information from First Databank (FDB).
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.